MedTrace Logo

Perforator Vein Injection for Symptomatic Venous Disease

NCT03363633 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-02-23

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to compare two treatment strategies for symptomatic venous stasis disease with and without venous ulcer. These treatments are compression therapy alone vs. sclerotherapy of refluxing perforating veins with compression.

Conditions

  • Venous Disease

Interventions

DRUG

sodium tetradecyl sulfate

Ultrasound-guided injection with sodium tetradecyl sulfate foam of refluxing perforating veins

DEVICE

Compression

20-30 mmHg compression stockings

Sponsors & Collaborators

  • American College of Phlebology

    collaborator OTHER

  • Ellen Dillavou

    lead OTHER

Principal Investigators

  • Ellen D Dillavou, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-10-01
Completion
2010-10-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03363633 on ClinicalTrials.gov